Income Statement
Quarterly Data
The income statement presents information on the financial results of a company business activities over a period of time. The income statement communicates how much revenue the company generated during a period and what cost it incurred in connection with generating that revenue.
Paying user area
Try for free
Abbott Laboratories pages available for free this week:
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to Abbott Laboratories for $24.99.
This is a one-time payment. There is no automatic renewal.
We accept:
Abbott Laboratories, consolidated income statement (quarterly data)
US$ in millions
Based on: 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31).
Revenue trends exhibit a cyclical pattern, with net sales peaking in early 2022 before experiencing a contraction throughout 2023. A recovery phase is observable starting in 2024, with sales trending upward toward the end of 2025 before a slight moderation in the first quarter of 2026. Gross profit margins followed a similar trajectory, contracting in 2023 but rebounding as sales volume recovered in 2024 and 2025.
- Operating Expense Management
- Research and development expenditures remained relatively stable over the analyzed period, generally fluctuating between 650 million and 780 million per quarter, indicating a consistent commitment to innovation regardless of sales volatility. Selling, general and administrative expenses showed relative stability until the first quarter of 2026, where a significant increase to 3.74 billion was recorded, contributing to a sharp decline in operating earnings for that period.
- Profitability and Margin Analysis
- Operating earnings experienced significant volatility, reaching a peak of 2.91 billion in March 2022 and hitting lows in late 2022 and early 2024. While operating performance showed a strong recovery trend through 2025, the abrupt increase in administrative costs in March 2026 suppressed this momentum, bringing operating earnings down to 1.35 billion.
- Net Earnings and Non-Operating Factors
- Net earnings typically align with operating performance, with the notable exception of the quarter ending December 31, 2024. During this period, net earnings spiked to 9.23 billion, driven by a substantial positive tax adjustment of 7.2 billion rather than operational growth. Interest income demonstrated a clear upward trend, rising from approximately 10 million in 2021 to a range of 70 million to 100 million in subsequent years, which partially offset consistent interest expenses.
- Tax and Other Income Trends
- Other income, net, remained positive throughout the period, providing a consistent secondary source of earnings. Taxes on earnings were generally stable as a percentage of pre-tax income, except for the anomalous tax benefit recorded in the fourth quarter of 2024, which significantly distorted the net income figure for that specific timeframe.